- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System | 174 | GlobeNewswire (Europe) | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 23.07. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry | 217 | GlobeNewswire (Europe) | Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation 510(k) package submission on track for calendar H2 2026, targeting planned... ► Artikel lesen | |
| 21.07. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market | 225 | GlobeNewswire (Europe) | NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 16.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.06. | Intelligent Bio Solutions starts interference study for FDA submission | 1 | Investing.com | ||
| 16.06. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | 263 | GlobeNewswire (Europe) | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| 02.06. | Intelligent Bio Solutions starts FDA study for fingerprint drug test | 2 | Investing.com | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 02.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.05. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year | 220 | GlobeNewswire (Europe) | Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building... ► Artikel lesen | |
| 13.05. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results | 283 | GlobeNewswire (Europe) | Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach... ► Artikel lesen | |
| 20.04. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | INBS completes penetration testing for FDA 510(k) submission | 5 | Investing.com | ||
| 17.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified | 384 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 02.04. | INBS completes clinical study for FDA drug screening submission | 3 | Investing.com | ||
| 02.04. | INBS schließt klinische Studie für FDA-Zulassungsantrag ab | 3 | Investing.com Deutsch | ||
| 02.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market | 230 | GlobeNewswire (Europe) | Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability... ► Artikel lesen | |
| 26.03. | Intelligent Bio Solutions receives European patent for drug testing tech | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,570 | -0,29 % | Turnaround-Aktien mit fast 200 % Kurspotenzial! Renk, Eckert & Ziegler, Power Metallic Mines! | Rund 50 % hat die Renk-Aktie seit Oktober 2025 verloren. Ist jetzt die Chance zum Einstieg gekommen? Jefferies sieht den fairen Wert immerhin bei 60 EUR. Die kommenden Halbjahreszahlen sollten überzeugen... ► Artikel lesen | |
| DRAEGERWERK | 112,80 | +3,11 % | EQS-News: Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026 | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Halbjahresbericht/Kapitalmarkttag
Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026... ► Artikel lesen | |
| TELADOC HEALTH | 5,792 | -0,38 % | Teladoc Health: Insurance Demand Outpaces Provider Capacity As BetterHelp Revenue Falls 12% | ||
| HIMS & HERS HEALTH | 26,300 | +9,22 % | Hims & Hers-Aktie: Folgt der nächste Wachstumsturbo? | Die Aktie von Hims & Hers Health hat sich in den vergangenen Jahren zu einem der spektakulärsten Wachstumswerte im Gesundheitssektor entwickelt. Die operativen Kennzahlen sprechen weiterhin für erhebliches... ► Artikel lesen | |
| BICO GROUP | 1,358 | +3,19 % | BICO Group AB: Bulletin from the Annual General Meeting in BICO Group AB (publ) | The following resolutions were passed at the Annual General Meeting (the "AGM") of BICO Group AB (publ) ("BICO" or the "Company") held today on 7 May 2026 in Gothenburg, Sweden.
Adoption of Income Statement... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,067 | -4,01 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,600 | +1,56 % | Dividendenbekanntmachungen (27.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATHOS IMMOBILIEN AG AT0000616701 - 0,8 EUR FVCBANKCORP INC US36120Q1013 0,07 USD 0,0615 EUR GAS PLUS SPA IT0004098510 - 0,25 EUR GERATHERM... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 151,60 | +3,38 % | Align Technology Inc. Reveals Fall In Q2 Bottom Line | WASHINGTON (dpa-AFX) - Align Technology Inc. (ALGN) reported a profit for second quarter that Drops, from last yearThe company's earnings totaled $108.294 million, or $1.51 per share. This compares... ► Artikel lesen | |
| CERENOME | 3,450 | 0,00 % | Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,010 | -16,39 % | NuGen Medical Devices Inc.: NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms | Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two... ► Artikel lesen | |
| HEALWELL AI | 0,415 | +2,22 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,920 | +7,87 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| SPINEWAY | 0,143 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen |
INTELLIGENT BIO SOLUTIONS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,38 % bei einem Aktienkurs von 1,835 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTELLIGENT BIO SOLUTIONS INC finden Sie auf Wallstreet Online.